Meanwhile, the phase III synchronous investigation of non-small cell lung cancer with the drug and ablative strategy trial investigated the role of first-line TKI therapy in patients with EGFR-mutated synchronous oligometastatic NSCLC (defined as ≤5 metastatic lesions). This evidence concerns the gene EGFR and non-small cell lung carcinoma.